Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2018

View Archived Issues

Probiotics: not all that

Overcoming aggravations in studying aggregation

Studying bacterial autoimmunity yields new CRISPR/Cas inhibitors

Getting to the bottom of complex genomics

New DPP IV inhibitor adapentpronitrile protects against diabetic neuronal injury

Researchers develop new rat model of post-traumatic joint stiffness of the knee

Researchers identify novel class of potent gamma-secretase modulators

Cyclacel initiates phase Ib/II study of sapacitabine with olaparib in BRCA-mutant breast cancer

Five Prime advances FIGHT study of bemarituzumab in gastric and gastroesophageal cancer

European Commission approves Keytruda with pemetrexed and chemotherapy for first-line NSCLC

Regulation, edification, sedation: 2018 Laskers honor research on complexity beyond DNA

Researchers present first-in-human data for AT-04A

Trevena patents new delta-opioid receptor modulators

Phase III study of Zerbaxa in HABP and VABP meets primary endpoints

SuPAR predicts chronic kidney disease progression in Black Americans

RQx Pharmaceuticals and Genentech present antibacterial compounds

Innate Tumor Immunity synthesizes new NLRP3 agonists for cancer

Prelude Therapeutics identifies new PRMT5 inhibitors

Dual sHE inhibitor/PPAR-gamma agonist shows benefits to treat metabolic syndrome and diabetes in rat

Janssen Pharmaceutica presents OGA inhibitors

Innate Pharma initiates phase I study of IPH-5401 with durvalumab in solid tumors

FINCH 2 study of filgotinib in rheumatoid arthritis meets primary endpoint

European Commission approves Veyvondi for adults with von Willebrand disease

Vital Therapies ceases development of ELAD cell-based therapy

DSMB recommends continuation of EPITOPE study of Viaskin Peanut in toddlers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...